Novo Nordisk warns consumers about counterfeit versions of Ozempic in US

(Reuters) - Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain in the United States.

The country's health regulator seized the counterfeit injections on April 9 and is investigating them.

Surging demand for Novo's Ozempic, chemically known as semaglutide, has given rise to concerns about unregulated, compounded and counterfeit medicines. Its weight-loss drug Wegovy also has the same active ingredient.

As the investigation continues, further analyses, including extensive visual examination and chemical testing of the seized, counterfeit product is underway. The U.S. Food and Drug Administration and Novo Nordisk do not yet have information about the drugs' identity, quality, or safety, the regulator said on its website.

Novo has advised retail pharmacies to purchase authentic Ozempic injections from authorized distributors and urged patients to check their product for any signs of counterfeiting before using.

(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber and Shilpi Majumdar)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Morgan Stanley Downgrades Novo Nordisk (NVO) to Underweight
• OpenAI meets with utility leaders on grid risks from rogue AI - report
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says